Sector News

Novartis’s Alcon eye-care unit to enter Swiss index after spin off

February 6, 2019
Life sciences

Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland’s 20 largest listed companies, market operator SIX said on Tuesday.

Information about any other changes to SMI and Switzerland’s other indexes will be released later, the bourse said.

Novartis last year announced the spin off of Alcon to the Basel drugmaker’s shareholders in the first half of this year.

Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.

By John Revill

Source: Reuters

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.